

Multimedia Appendix 1. Odds ratios for demographic characteristics and stated likelihood of using different pre-exposure prophylaxis modalities among MSM participating in an online survey, United States, April-July 2015

Characteristic	Odds Ratio^a (95% CI)	Type 3 P value	Odds Ratio^a (95% CI)	Type 3 P value	Odds Ratio^a (95% CI)	Type 3 P value
Systemic Modalities						
	Daily oral pills		Injection ^b		On-demand pills ^c	
Race/Ethnicity		0.011		0.458		0.372
White, not Hispanic	Reference		Reference		Reference	
Black, not Hispanic	3.10 (1.35-7.13)		1.05 (0.55-2.01)		1.45 (0.68-3.09)	
Hispanic	1.36 (0.91-2.03)		1.32 (0.92-1.91)		1.32 (0.87-1.99)	
Other	1.76 (0.95-3.25)		1.23 (0.71-2.11)		1.37 (0.74-2.54)	
Age (years)		0.015		0.708		0.158
18-24	1.52 (1.05-2.20)		1.05 (0.75-1.48)		1.04 (0.70-1.54)	
25-29	1.00 (0.68-1.49)		1.16 (0.80-1.68)		0.76 (0.50-1.15)	
30-34	Reference		Reference		Reference	
Highest level of education		0.005		0.205		0.158
High School or less	Reference		Reference		Reference	
Some college	0.76 (0.39-1.47)		1.07 (0.61-1.85)		0.53 (0.25-1.09)	
Bachelor degree	0.51 (0.27-0.98)		1.48 (0.85-2.55)		0.54 (0.26-1.11)	
Any graduate school	0.43 (0.22-0.83)		1.30 (0.75-2.26)		0.44 (0.21-0.91)	
U.S. Census region		0.645		0.766		0.785
Midwest	0.99 (0.63-1.55)		0.92 (0.60-1.39)		0.90 (0.56-1.44)	
Northeast	0.93 (0.61-1.43)		0.80 (0.54-1.21)		0.79 (0.51-1.24)	
South	1.17 (0.79-1.73)		0.91 (0.63-1.31)		0.90 (0.60-1.37)	
West	Reference		Reference		Reference	
Topical Modalities						
	Penis gel, before		Penis gel, after		Rectal gel, before	
Race/Ethnicity		0.037		0.115		0.002
White, not Hispanic	Reference		Reference		Reference	
Black, not Hispanic	6.59 (1.54-28.24)		2.82 (1.05-7.59)		4.28 (1.73-10.61)	
Hispanic	1.27 (0.81-2.00)		1.32 (0.85-2.06)		1.45 (0.97-2.17)	
Other	1.65 (0.76-3.59)		0.83 (0.40-1.70)		1.85 (0.96-3.56)	
Age (years)		0.056		0.712		0.680
18-24	1.61 (1.06-2.45)		0.99 (0.65-1.50)		0.88 (0.59-1.31)	
25-29	1.16 (0.75-1.79)		0.86 (0.56-1.34)		0.83 (0.54-1.26)	
30-34	Reference		Reference		Reference	
Highest level of education		0.342		0.851		0.073
High School or less	Reference		Reference		Reference	
Some college	1.03 (0.47-2.24)		0.80 (0.38-1.67)		0.62 (0.31-1.24)	
Bachelor degree	0.91 (0.43-1.93)		0.89 (0.43-1.83)		0.50 (0.25-0.98)	

Any graduate school	0.71 (0.33-1.51)		0.78 (0.38-1.61)		0.44 (0.22-0.88)
U.S. Census region		0.894		0.979	0.470
Midwest	0.82 (0.49-1.36)		1.06 (0.64-1.73)		0.78 (0.48-1.25)
Northeast	0.92 (0.56-1.50)		0.95 (0.59-1.53)		0.73 (0.46-1.14)
South	0.90 (0.57-1.41)		0.97 (0.63-1.50)		0.91 (0.60-1.38)
West	Reference		Reference		Reference

Topical Modalities, continued

	Rectal gel, after		Suppository, before		Suppository, after
Race/Ethnicity		0.137		0.057	0.548
White, not Hispanic	Reference		Reference		Reference
Black, not Hispanic	2.52 (1.14-5.58)		2.69 (1.26-5.77)		1.28 (0.60-2.71)
Hispanic	1.03 (0.69-1.54)		1.30 (0.86-1.97)		0.81 (0.54-1.22)
Other	1.25 (0.66-2.35)		1.15 (0.61-2.17)		1.22 (0.68-2.22)
Age (years)		0.254		0.691	0.113
18-24	0.85 (0.57-1.26)		0.87 (0.57-1.31)		0.73 (0.49-1.09)
25-29	0.70 (0.46-1.08)		0.83 (0.53-1.29)		0.63 (0.41-0.97)
30-34	Reference		Reference		Reference
Highest level of education		0.041		0.266	0.735
High School or less	Reference		Reference		Reference
Some college	0.81 (0.40-1.63)		0.62 (0.32-1.21)		0.76 (0.39-1.49)
Bachelor degree	0.54 (0.27-1.07)		0.53 (0.27-1.02)		0.73 (0.38-1.41)
Any graduate school	0.52 (0.26-1.05)		0.55 (0.28-1.07)		0.85 (0.44-1.65)
U.S. Census region		0.845		0.784	0.446
Midwest	1.10 (0.68-1.77)		0.83 (0.51-1.37)		0.73 (0.46-1.18)
Northeast	0.91 (0.58-1.42)		0.82 (0.51-1.31)		0.73 (0.47-1.14)
South	1.05 (0.70-1.59)		0.96 (0.63-1.46)		0.75 (0.50-1.12)
West	Reference		Reference		Reference

^aCompares respondents that are “somewhat likely” or “very likely” to respondents that indicated they are “somewhat unlikely” or “very unlikely” to use each modality. Responses that were “neither likely or unlikely” were set to missing. Wald chi-square type 3 *P* values were used with an alpha=0.05.

^bEvery 1-3 months

^cTwo pills 24 hours before sex and two one-pill doses after.